Results 43,581-43,600 of 49,836 for speaker:Stephen Donnelly
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Stephen Donnelly: Is the EU taking any steps in that regard?
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Stephen Donnelly: Are there any EU prize funds? There are many ways it can be done, one of which is that we just do it ourselves. We can publicly fund universities, research centres or whatever, or create economic incentives for the private sector to do the kind of work we want it to do rather than it just chasing profit all the time, or both. Does the EU offer any such incentives?
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Stephen Donnelly: On the other approach, namely, publicly funded research of drugs, perhaps all the drugs that are discussed at the committee are produced by private pharmaceutical firms. Are there examples of breakthrough or orphan drugs that have come from public research institutes in, say, the past five years?
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Stephen Donnelly: My question was whether there are examples. We know about Spinraza and Orkambi and we can list other private drugs. Are there examples of drugs that have come through public institutions and are being deployed as such, that is, not drugs which have been nobbled by private interests?
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Stephen Donnelly: I am asking a different question. Have any of these drugs come from publicly owned institutions, such as universities or public research centres?
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Stephen Donnelly: Dr. Harkin has referred to public private partnership but I am referring to public only. I am trying to understand whether it is just the reality that the private companies must carry out the work and we must put in legal and financial ways of securing the intellectual property, IP, or is there publicly-owned research infrastructure globally that can do it? Are we reliant on the private...
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Stephen Donnelly: The research and development was done by publicly employed scientists.
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Stephen Donnelly: Is there a recommendation on what the IP protection of 20 years should be reduced to?
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Stephen Donnelly: It sounds as though we are largely reliant on the private sector to do the work.
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Stephen Donnelly: I acknowledge that Dr. Harkin was able to refer to one public private partnership but it sounds as though the private sector will do the vast majority of the work in this regard. If the IP is removed, which would remove the ability of companies for a time-limited period to charge a healthy margin, is there another model, given that the companies will still need to follow the money? Is there...
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Stephen Donnelly: Let us say, in the case of a global pharmaceutical company, that a decision is made at a governmental or EU level to target lung cancer. While I have not seen the figures for a while, ten years ago the research and development cost for a typical blockbuster drug was approximately $5 billion, although I imagine it has risen considerably. Is the proposal that EU funds would be created whereby...
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Stephen Donnelly: Let us say that it is somewhere between $1 billion and $5 billion. Is the idea that we would block-grant the pharmaceutical companies?
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Stephen Donnelly: I thank the witnesses.
- Withdrawal of the United Kingdom from the European Union (Consequential Provisions) Bill 2019: Committee Stage (5 Mar 2019)
Stephen Donnelly: I move amendment No. 9:In page 10, between lines 3 and 4, to insert the following:"(b) When an order is made under subsection (1)(a) which involves the spending of public monies, the order must be made with the consent of the Minister for Public Expenditure and Reform. (c) When an order is made under subsection (1)(a) which involves the raising of public monies, the order must be made with...
- Withdrawal of the United Kingdom from the European Union (Consequential Provisions) Bill 2019: Committee Stage (5 Mar 2019)
Stephen Donnelly: I move amendment No. 20:In page 10, line 30, after "Reform," to insert "when such consent is required in section 75A(1)(b) and (c)".
- Withdrawal of the United Kingdom from the European Union (Consequential Provisions) Bill 2019: Committee Stage (5 Mar 2019)
Stephen Donnelly: Before responding to the Minister, I have a question on the order for this session. Has it been agreed to guillotine this session?
- Withdrawal of the United Kingdom from the European Union (Consequential Provisions) Bill 2019: Committee Stage (5 Mar 2019)
Stephen Donnelly: Would it be possible to put the time on the clocks in order that we can keep an eye on it? If votes are called, what will the procedure be? Will there be time at the end of given periods to call votes or if we are in the middle of debate when we hit that time, will there be opportunities to call votes?
- Withdrawal of the United Kingdom from the European Union (Consequential Provisions) Bill 2019: Committee Stage (5 Mar 2019)
Stephen Donnelly: The debate on each Part is being guillotined. Let us say we reach zero on the clock and are in the middle of debate, will the opportunity to call a vote or press an amendment be lost?
- Withdrawal of the United Kingdom from the European Union (Consequential Provisions) Bill 2019: Committee Stage (5 Mar 2019)
Stephen Donnelly: If we were to reach the end mid-debate-----
- Withdrawal of the United Kingdom from the European Union (Consequential Provisions) Bill 2019: Committee Stage (5 Mar 2019)
Stephen Donnelly: -----there would be no opportunity to press an amendment.